Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05142774 · ClinicalTrials.gov registry record · Phase 3
Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
A Phase 3 study, sponsored by Organon and.
- Completed
- Registry status
- Phase 3
- Development phase
- 728
- Enrollment target
NCT05142774 is a Phase 3 study that has completed, run by Organon and. The registered enrollment target is 728 participants.
The verdict
NCT05142774, a Phase 3 study, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 728 participants
- Enrollment target
Study Summary
This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in the DMVT-505-2104 study, or directly enrolled into this study. This study will consist of up to 48 weeks of treatment and a 1 week safety follow-up period.
Interventions
- DRUG Tapinarof cream, 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2021-10-28 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05142774
The ClinicalTrials.gov registry entry for NCT05142774 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 728 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tapinarof cream, 1% is the first listed.
NCT05142774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05142774 about?
NCT05142774 is a clinical study titled "Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis". This is an open-label, long-term multicenter, study to evaluate the safety and efficacy of topical tapinarof cream, 1% in subjects with atopic dermatitis. Subjects in this study have completed treatment in one of two Phase 3 pivotal studies (DMVT-505-3101 or DMVT-505-3102) or completed treatment in ...
What is the current status of trial NCT05142774?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 728 participants. The study started on 2021-10-28. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT05142774?
The interventions under investigation include: Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT05142774?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.